natgillin/translations-raw huggingface dataset:
Patients were randomly assigned to receive pembrolizumab at a dose of mg/kg every 3 weeks or 10 mg/kg every 3 weeks.
Bolnike so randomizirali na zdravljenje s pembrolizumabom v odmerku 2 mg/kg na 3 tedne ali 10 mg/kg na 3 tedne.
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Bolnike z izhodiščno koncentracijo HIV-1 RNA najmanj 1500 kopij/ml so stratificirali po starosti (2 do < 6 let, 6 do < 12 let in 12 do 18 let) in jih naključno razvrstili v zdravljenje z enim od naslednjih dveh režimov odmerjanja tipranavirja ob ritonavirju: odmerek po 375 mg/m2 in 150 mg/m2 primerjan z odmerkom po 290 mg/m2 in 115 mg/m2 ob osnovnem zdravljenju z najmanj dvema protiretrovirusnima zdraviloma, ki nista zaviralca proteaze, optimiziranem s testiranjem genotipske odpornosti.
Patients were required to have a baseline HIV-1 RNA concentration of at least 1500 copies/ml, were stratified by age (2 to < 6 years, 6 to < 12 years and 12 to 18 years) and randomized to receive one of two tipranavir with ritonavir dose regimens: 375 mg/m2/150 mg/m2 dose, compared to the 290 mg/m2/115 mg/m2 dose, plus background therapy of at least two non- protease inhibitor antiretroviral medicinal products, optimized using baseline genotypic resistance testing.
Bolnike z izhodiščno koncentracijo HIV-1 RNA najmanj 1500 kopij/ml so stratificirali po starosti (2 do < 6 let, 6 do < 12 let in 12 do 18 let) in jih naključno razvrstili v zdravljenju z enim od naslednjih dveh režimov odmerjanja tipranavirja ob ritonavirju: odmerek po 375 mg/m2 in 150 mg/m2 primerjan z odmerki po 290 mg/m2 in 115 mg/m2 ob osnovnem zdravljenju z najmanj dvema protiretrovirusnima zdraviloma, ki nista zaviralca proteaze, optimiziranem s testiranjem genotipske odpornosti.
Patients were required to have an HIV-1 RNA < 50 copies/ml and CD4 count > 300 cells/mm3 at screening.
Bolniki so morali imeti na presejalnem pregledu < 50 kopij RNK HIV-1/ml, število celic CD4 ≥ 300 celic/mm3.
Patients were required to have experienced disease progression during, or within 4 months after the last dose of first-line therapy and with ECOG PS 0-1.
Vključili so bolnike, pri katerih je bolezen napredovala v času zdravljenja prve izbire ali v 4 mesecih po zadnjem odmerku zdravljenja prve izbire, ter ki so imeli status zmogljivosti 0-1 po ECOG.
Patients were required to have experienced disease progression during, or within 4 months after the last dose of, first-line therapy for metastatic disease, or during adjuvant treatment or within 6 months after the last dose of adjuvant therapy, and had ECOG PS 0-1.
Vključili so bolnike, pri katerih je bolezen napredovala v času zdravljenja prve izbire ali v 4 mesecih po zadnjem odmerku zdravljenja pri metastatski bolezni, ali med dopolnilnim zdravljenjem ali v 6 mesecih po zadnjem odmerku dopolnilnega zdravljenja, ter ki so imeli status zmogljivosti 0-1 po ECOG.
Patients were required to have received adequate previous treatment with at least one prior combination chemotherapy regimen.
Bolniki so morali prejeti ustrezno predhodno zdravljenje z vsaj eno predhodno kombinirano kemoterapevtsko shemo.
Patients were required, among others, to have histological confirmation of predominant clear cell RCC, radiographic evidence of disease progression according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1), one prior VEGF-targeted therapy and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
Bolniki so med drugim morali imeti histološko potrditev RCC s prevladujočimi svetlimi celicami, rentgenski dokaz napredovanja bolezni po merilih za ocenjevanje odziva pri čvrstih tumorjih, verzija 1.1 (Response Evaluation Criteria in Solid Tumours Version 1.1 - RECIST 1.1), eno predhodno zdravljenje, usmerjeno v VEGF, in status zmogljivosti (Performance Status – PS) Eastern Cooperative Oncology Group (ECOG) 0 ali 1.
Patients were stratified according to region, iNHL subtype (follicular versus non-follicular), rituximab-refractory type (whether refractory to prior rituximab monotherapy or rituximab in combination with chemotherapy) and the number of prior therapies (≤2 versus >2).
Bolnike so stratificirali glede na regijo, podvrsto iNHL (folikularni ali nefolikularni), vrsto refraktarnosti na rituksimab (refraktaren na predhodno monoterapijo z rituksimabom ali na rituksimab v kombinaciji s kemoterapijo) in število predhodnih zdravljenj (≤ 2 ali > 2).
Patients were stratified at randomization by age (≤75 versus >75 years), stage (ISS Stages I and II versus Stage III), and country.
Pri randomizaciji so bolnike stratificirali po starosti (≤75 proti >75 let), stadiju (ISS stadija I in II proti stadiju III), in državi.
Patients were stratified by age, enrolling adolescents first and then successively younger children.
Bolniki z virološkim neuspehom v preteklosti niso bili izključeni.
Patients were stratified by hemoglobin level (≤13 g/dL vs. >13 g/dL for males and ≤11.5 g/dL vs >11.5 g/dL for females) and corrected serum calcium (≥10 mg/dL vs. <10 mg/dL).
Bolnike so stratificirali po koncentraciji hemoglobina (≤ 13 g/dl proti > 13 g/dl za moške in ≤ 11,5 g/dl proti > 11,5 g/dl za ženske) in popravljenem serumskem kalciju (≥ 10 mg/dl proti < 10 mg/dl).
Patients were stratified by the class of the third agent in their prior treatment regimen.
Bolniki so bili stratificirani glede na razred tretje učinkovine v predhodnem režimu zdravljenja.
Patients were switched from efavirenz/emtricitabine/tenofovir disoproxil to Eviplera without a washout period.
Bolniki so prešli z zdravljenja z efavirenzom/emtricitabinom/dizoproksiltenofovirijevim fumaratom na zdravilo Eviplera brez obdobja izpiranja.
Patients were switched without a washout period.
Bolniki so prešli z zdravljenja brez obdobja izpiranja.
Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.
Bolnikom so postopoma povečevali odmerek zdravila Karvea od 75 mg do vzdrževalnega odmerka 300 mg, odmerek amlodipina od 2,5 do 10 mg, oziroma placeba, kot so ga prenesli.
Patients were to have ECOG performance status score of 0 or 1.
Bolniki so morali imeti oceno stanja telesne zmogljivosti po lestvici ECOG 0 ali 1.
Patients were to receive either medicine for as long as they could until their disease got worse or their treatment became too toxic for them.
Bolniki so konkretno zdravilo prejemali, kolikor dolgo so lahko, preden se je bolezen poslabšala ali je zdravljenje zanje postalo preveč strupeno.
Patients were to undergo an invasive strategy for further management after receiving study drug for 12 to 96 hours.
Bolniki so imeli po 12- do 96-urnem prejemanju raziskovanega zdravila predvideno invazivno nadaljnje vodenje.
Patients were treated at doses of imatinib of 260 mg/m2/day (n = 5), 340 mg/m2/day (n = 9), 440 mg/m2/day (n = 7) and 570 mg/m2/day (n = 5).
Bolniki so bili zdravljeni z odmerki imatiniba 260 mg/m²/dan (n = 5), 340 mg/m²/dan (n = 9), 440 mg/m²/dan (n = 7) in 570 mg/m²/dan (n = 5).
Patients were treated at doses of imatinib of 260 mg/m2/day (n=5), 340 mg/ m2/day (n=9), 440 mg/ m2/day (n=7) and 570 mg/ m2/day (n=5).
Bolniki so bili zdravljeni z odmerki imatiniba 260 mg/m2/dan (n=5), 340 mg/m2/dan (n=9), 440 mg/m2/dan (n=7) in 570 mg/m2/dan (n=5).
Patients were treated for approximately 12 weeks with tasimelteon 20 mg one hour prior to bedtime, at the same time every night.
Bolniki so približno 12 tednov jemali 20 mg tasimelteona eno uro pred spanjem, vsak večer ob istem času.
Patients were treated for up to 5 years.
Bolnike so zdravili do 5 let.
Patients were treated in hospital until clinical stabilisation, revascularisation or discharge.
Bolniki so se bolnišnično zdravili, dokler se njihovo klinično stanje ni stabiliziralo, dokler ni bila izvedena revaskularizacija ali dokler bolnik ni bil odpuščen iz bolnišnice.
Patients were treated until disease progression or unacceptable toxicity occurred.
Bolniki so bili zdravljeni, dokler se ni pojavilo napredovanje bolezni ali nesprejemljivi toksični učinki.
Patients were treated with bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a further 12 weeks.
Štiri tedne so prejemali bosentan 62,5 mg dvakrat na dan, nato pa nadaljnjih 12 tednov 125 mg dvakrat na dan .
Patients were treated with HyQvia at either 3- or 4-week treatment intervals for a total of 12 months (following a brief titration period).
Bolniki, zdravljeni z zdravilom HyQvia bodisi s tri-bodisi s štiritedenskimi presledki skupno 12 mesecev (po kratkem obdobju titriranja).
Patients were treated with imatinib 340 mg/ m2/day, with no interruptions in the absence of dose limiting toxicity.
Bolniki so bili zdravljeni z odmerki imatiniba340 mg/m2/dan brez prekinitev; toksičnih učinkov, zaradi katerih bi zmanjševali odmerjanje, ni bilo.
Patients were treated with imatinib 340 mg/m2/day, with no interruptions in the absence of dose limiting toxicity.
Bolniki so bili zdravljeni z odmerki imatiniba340 mg/m2/dan brez prekinitev; toksičnih učinkov, zaradi katerih bi zmanjševali odmerjanje, ni bilo.
Patients were treated with LEMTRADA 12 mg/day (N=108) or 24 mg/day (N=108) administered once per day for 5 days at Month 0 and for 3 days at Month 12 or subcutaneous IFNB-1a 44 µg (N=107) administered 3 times per week for 3 years.
Bolniki so bili zdravljeni z odmerkom zdravila LEMTRADA 12 mg/dan (N=108) ali 24 mg/dan (N=108), ki so ga prejeli enkrat dnevno 5 dni v 0. mesecu in 3 dni v 12. mesecu, ali subkutanim IFNB-1a 44 µg (N=107), ki so ga prejemali 3-krat tedensko 3 leta.
Patients were treated with oral daily dosing of Erivedge at 150mg.
Bolniki so se zdravili z zdravilom Erivedge, ki so ga prejemali vsak dan peroralno v odmerku 150 mg.
Patients were treated with ranibizumab 0.5 mg pro re nata (PRN) in the same eye as the core study (D2301 RESTORE).
Bolniki so prejemali ranibizumab 0,5 mg po shemi odmerjanja pro re nata (PRN, po potrebi) v isto oko kot v osnovni študiji z oznako D2301 (RESTORE).
Patients were treated with Signifor at either 0.6 mg twice a day or 0.9 mg twice a day.
Bolniki so zdravilo Signifor jemali bodisi dvakrat na dan po 0,6 mg bodisi dvakrat na dan po 0,9 mg.
Patients were virologically suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months before switching.
Bolniki so imeli pred prehodom virusno supresijo (HIV-1 RNA < 50 kopij/ml) vsaj 6 mesecev.
Patients who accidentally received too much Thyrogen have reported nausea, weakness, dizziness, headache, vomiting and hot flashes.
Bolniki, ki so nenamerno prejeli prevelik odmerek zdravila Thyrogen, so poročali o, oslabelosti, omotičnosti, glavobolu, bruhanju in vročinskih oblivih.
Patients who achieved a clinical response after receiving vedolizumab at Week 0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open-label extension study and receive vedolizumab every four weeks.
Bolniki s kliničnim odzivom po prejemu vedolizumaba na 0. in 2. teden, ki so nato bili randomizirani na placebo (od 6. do 52. tedna), pri čemer se je klinični odziv izgubil, so lahko vstopili v odprto podaljšano študijo in so vedolizumab prejemali na vsake štiri tedne.
Patients who achieved a response (defined as clearing of the CSF of malignant cells in the absence of progression of neurological symptoms) went on to receive Consolidation and Maintenance therapy for up to 29 weeks.
Bolniki, ki so se odzvali (odziv je bil opredeljen kot odstranitev malignih celic iz cerebrospinalne tekočine v odsotnosti napredovanja nevroloških simptomov), so prejemali konsolidacijsko in vzdrževalno zdravljenje največ 29 tednov.
Patients who achieved PASI-50 at Week 32
bolniki, ki so dosegli PASI-50 v 32. tednu
Patients who achieved PASI-75 at Week 32
bolniki, ki so dosegli PASI-75 v 32. tednu
Patients who also have major depression should start with 60 mg once a day.
Bolniki, ki imajo tudi hujše depresivne motnje, morajo začeti s 60 mg enkrat na dan.
Patients who are allergic to peanut or soya must not take these tablets.
Bolniki, ki so alergični na arašide ali sojo, ne smejo jemati teh tablet.
Patients who are already on immediate-release tablets or oral suspension can switch to prolonged- release tablets without lead-in period.
Bolniki, ki se že zdravijo s tabletami s takojšnjim sproščanjem ali peroralno suspenzijo, lahko zdravilo zamenjajo s tabletami s podaljšanim sproščanjem brez uvajalnega obdobja.
Patients who are already on immediate-release tablets or oral suspension can switch to prolonged- release tablets without lead-in period.
Bolniki, ki se že zdravijo s tabletami s takojšnjim sproščanjem ali peroralno suspenzijo, lahko zdravilo zamenjajo za obliko s podaljšanim sproščanjem brez uvajalnega obdobja.
Patients who are at risk of infection because they do not have sufficient antibodies (proteins naturally found in the blood that help the body to fight infections and other diseases).
bolnikih, pri katerih obstaja nevarnost okužbe zaradi nezadostnega števila protiteles (beljakovin, ki se naravno nahajajo v krvi ter pomagajo telesu pri premagovanju okužb in drugih bolezni).
Patients who are being treated with chemotherapy that is moderately or highly capable of triggering nausea and vomiting may still experience vomiting despite treatment with appropriate therapy, including SANCUSO.
Pri bolnikih, ki se zdravijo s kemoterapevtiki, ki zmerno ali močno prožijo navzeo in bruhanje, se lahko še vedno pojavlja bruhanje kljub zdravljenju z ustreznimi zdravili, med drugim z zdravilom SANCUSO.
Patients who are blind or have poor vision, must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.
Bolnikom, ki so slepi ali slabo vidijo, je treba naročiti, da si morajo vedno poiskati pomoč pri osebi, ki dobro vidi in je usposobljena za uporabo injekcijskega peresnika.
Patients who are born with a reduced ability or inability to produce immunoglobulins (primary immunodeficiencies (PID)).
Bolniki s prirojeno zmanjšano sposobnostjo ali nesposobnostjo proizvajanja imunoglobulinov (primarna imunska pomanjkljivost (PID– primary immunodeficiencies)).
Patients who are concerned about their fertility while taking Glivec are advised to consult with their doctor.
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Glivec, naj se posvetujejo s svojim zdravnikom.
Patients who are concerned about their fertility while taking Imatinib Accord are advised to consult with their doctor.
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib Accord, naj se posvetujejo s svojim zdravnikom.
Patients who are concerned about their fertility while taking Imatinib Actavis are advised to consult with their doctor.
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib Actavis, naj se posvetujejo s svojim zdravnikom.
Patients who are concerned about their fertility while taking Imatinib medac are advised to consult with their doctor.
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib medac, naj se posvetujejo s svojim zdravnikom.
Patients who are concerned about their fertility while taking Imatinib Teva are advised to consult with their doctor.
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib Teva, naj se posvetujejo z zdravnikom.
Patients who are constipated should be monitored carefully while being treated with Renvela.
Zaprte bolnike je potrebno med zdravljenjem z zdravilom Renvela skrbno nadzorovati.
Patients who are constipated should be monitored carefully while being treated with Sevelamer carbonate Zentiva.
Zaprte bolnike je potrebno med zdravljenjem z zdravilom Sevelamer carbonate Zentiva skrbno nadzorovati.
Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Corbilta tablet strengths can be directly transferred to corresponding Corbilta tablets.
Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Corbilta, lahko neposredno preidejo na uporabo tablet zdravila Corbilta.
Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Corbilta tablet strengths can be directly transferred to corresponding Corbilta tablets.
Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Corbilta, lahko neposredno preidejo na uporabo tablet zdravilo Corbilta.
Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Levodopa/Carbidopa/Entacapone Orion tablet strengths can be directly transferred to corresponding Levodopa/Carbidopa/Entacapone Orion tablets.
Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Levodopa/Carbidopa/Entacapone Orion, lahko neposredno preidejo na uporabo tablet zdravila Levodopa/Carbidopa/Entacapone Orion.
Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Levodopa/Carbidopa/Entacapone Orion tablet strengths can be directly transferred to corresponding Levodopa/Carbidopa/Entacapone Orion tablets.
Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Levodopa/Carbidopa/Entacapone Orion, lahko neposredno preidejo na uporabo tablet zdravilo Levodopa/Carbidopa/Entacapone Orion.
Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Stalevo tablet strengths can be directly transferred to corresponding Stalevo tablets.
Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Stalevo, lahko neposredno preidejo na uporabo tablet zdravila Stalevo.
Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Stalevo tablet strengths can be directly transferred to corresponding Stalevo tablets.
Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Stalevo, lahko neposredno preidejo na uporabo tablet zdravilo Stalevo.
Patients who are CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor, and patients who are CYP2D6 poor metabolisers (PMs) taking a strong CYP3A inhibitor.
Bolniki, ki so vmesni presnavljalci (IM) ali hitri presnavljalci (EM) encima CYP2D6 in jemljejo močan ali zmeren zaviralec encima CYP2D6 sočasno z močnim ali zmernim zaviralcem encima CYP3A in bolniki, ki so slabi presnavljalci (PM) encima CYP2D6 in jemljejo močan zaviralec encima CYP3A.
Patients who are known to be homozygous for UGT1A1*28 and without drug related toxicities during the first cycle of therapy (reduced dose of 60 mg/m2) may have the dose of ONIVYDE increased to a total dose of 80 mg/m2 in subsequent cycles based on individual patient tolerance.
Pri bolnikih z znano homozigotnostjo za UGT1A1*28, pri katerih se v prvem ciklu zdravljenja (z zmanjšanim odmerkom 60 mg/m2) toksičnost zdravila ne pojavi, se odmerek zdravila ONIVYDE v naslednjih ciklih lahko poveča do skupnega odmerka 80 mg/m2, na podlagi tega, kako ga posamezen bolnik prenaša.
Patients who are not controlled by, contraindicated to, or intolerant to two or more systemic therapies *
Bolniki, ki niso bili nadzorovani, ki so imeli kontraindikacije za ali niso prenašali dveh ali več sistemskih terapij
Patients who are prescribed Darzalex will be provided with a patient alert card with similar information.
Bolniki, ki jim bo zdravilo Darzalex predpisano, bodo prejeli kartico s podobno informacijo.
Patients who are previously untreated
Predhodno nezdravljeni bolniki
Patients who are receiving, or who have received, medicinal products known to cause hypokalemia or hypomagnesaemia, such as diuretics or amphotericin B, may be at higher risk for torsade de pointes.
Pri bolnikih, ki prejemajo ali so prejemali zdravila, za katera je znano, da povzročajo hipokaliemijo ali hipomagneziemijo, kot so diuretiki ali amfotericin B, je večje tveganje nastanka aritmije torsade de pointes.
Patients who are responding to up to 6 weeks treatment using tacrolimus ointment twice daily (lesions cleared, almost cleared or mildly affected) are suitable for maintenance treatment.
Bolniki, ki se odzovejo na do 6 tednov trajajoče zdravljenje z mazilom s takrolimusom dvakrat na dan (spremembe izginejo, skoraj izginejo ali koža ostane le še rahlo prizadeta), so primerni za vzdrževalno zdravljenje.
Patients who are severely immunocompromised (e.g. patients with severe congenital or acquired cellular and/or humoral immune deficiency) (see section 4.4).
Bolniki, ki so zelo imunokompromitirani (npr. bolnikih s hudo prirojeno ali pridobljeno celično in/ali humoralno imunsko pomanjkljivostjo) (glejte poglavje 4.4).
patients who are still growing;
pri bolnikih, ki še rastejo;
Patients who are switching from a ‘chelating agent’ (another type of medicine for Wilson’s disease) to Wilzin should continue to take the chelating agent for two to three weeks after starting Wilzin, because Wilzin takes some time to start working fully.
Bolniki, ki z jemanja „kelatorjev“ (druge vrste zdravila za Wilsonovo bolezen) prehajajo na zdravilo Wilzin, morajo kelatorje jemati še dva do tri tedne po začetku jemanja zdravila Wilzin, saj je za pričetek popolnega delovanja zdravila Wilzin potreben določen čas.
Patients who are taking concomitant medicinal products that shorten the half- life of perampanel (see section 4.5) should be titrated no more frequently than at 1-week intervals.
Bolnike, ki sočasno uporabljajo zdravila, ki skrajšajo razpolovni čas perampanela (glejte poglavje 4.5), titriramo v intervalih, ki niso krajši kot 1 teden.
Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 1- week intervals.
Bolnike, ki sočasno uporabljajo zdravila, ki skrajšajo razpolovni čas perampanela (glejte poglavje 4.5), titriramo v intervalih, ki niso krajši kot 1 teden.
Patients who are taking ethinylestradiol -containing medicinal products (i.e. most combined oral contraceptives or contraceptive vaginal rings) must switch to an alternative method of contraception (e.g., progestin only contraception or non-hormonal methods) prior to initiating Exviera with ombitasvir/paritaprevir/ritonavir therapy (see sections 4.3 and 4.5).
Bolnice, ki uporabljajo zdravila z etinilestradiolom (tj. večina kombiniranih peroralnih kontraceptivov ali kontracepcijskih vaginalnih obročkov), morajo preiti na drugačen način kontracepcije (npr. na samo progestinsko kontracepcijo ali na nehormonske načine), preden začnejo zdravljenje z zdravilom Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir (glejte poglavji 4.3 in 4.5).
Patients who are to undergo surgery or other invasive procedures
Bolniki, ki morajo na operacijo ali drug invaziven poseg
Patients who are treated with Cosentyx and have Crohn’s disease should be followed closely.
Bolnike, ki prejemajo zdravilo Cosentyx in imajo Crohnovo bolezen, je treba skrbno spremljati.
Patients who are treated with Soliris less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination.
Bolniki, ki so zdravljeni z zdravilom Soliris prej kot 2 tedna po cepljenju proti meningokoku, morajo prejeti ustrezno profilaktično antibiotično zdravljenje, dokler od cepljenja ne mineta 2 tedna.